Integration Kann nicht Zurückhaltung gkiozos ioannis Konvergenz Humanistisch Schlichter
Exceptional antitumor responses beyond immune checkpoint inhibition in non-small cell lung cancer patients: insights into optimal therapy sequencing - Charpidou - Journal of Thoracic Disease
Interferon‐induced sarcoidosis - Alazemi - 2006 - International Journal of Clinical Practice - Wiley Online Library
Home - 28th World Congress of Lymphology
PDF) Psychological correlates of sleep quality in lung cancer patients under chemotherapy: a single-center cross-sectional study | Dimitrios Papadopoulos - Academia.edu
Ioannis Gkiozos Pulmonologist- CSSLight
Histones and lung cancer: are the histone deacetylases a promising therapeutic target? | SpringerLink
Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival. - Abstract - Europe PMC
Ioannis GKIOZOS | Consultant | National and Kapodistrian University of Athens, Athens | uoa | Oncology Unit, 3rd Internal Medicine Department
Cureus | Malignant Superior Vena Cava Syndrome: State of the Art
Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors - Journal of Thoracic Oncology
Clinical Significance of Smoking Cessation in Subjects With Cancer: A 30-Year Review | Respiratory Care
Accelerated hypofractionated radiotherapy for advanced lung cancer | Journal of Radiotherapy in Practice | Cambridge Core
PDF] Clinical Significance of Smoking Cessation in Subjects With Cancer: A 30-Year Review | Semantic Scholar
Επίπεδα VEGF σε πλευριτική συλλογή και περιφερικό δείγμα αίματος σε ασθενείς με καρκίνο πνεύμονα: η κλινική τους σημασία
8th Lung Cancer Network Virtual Symposium
Clinical utility of thoracic endosonography (EBUS/EUS-b) in mediastinal staging of patients with non-small cell lung cancer: comparison with integrated PET/CT—a real-life prospective study in Greece - Chrysikos - Journal of Thoracic Disease
PET/CT and brain MRI role in staging NSCLC: prospective assessment of the accuracy, reliability and cost–effectiveness | Lung Cancer Management
Ioannis VATHIOTIS | Postdoctoral Associate | Doctor of Medicine | Yale University, CT | YU | Department of Pathology and Pediatric Pathology